Recent Company News

• 07:06 AM ET Sep 02, 2026
  

  Can-Fite provides update on ongoing phase III study of namodenoson in HCC; considering earlier timing for planned interim analysis (500.00a, +5.00)

• 04:20 PM ET Aug 28, 2026
  

  Can-Fite BioPharma files $100M mixed shelf; enters into ATM offering agreement for up to $1.1M of ADSs - F-3 (508.00a, 0.00)

• 07:03 AM ET Aug 17, 2026
  

  Can-Fite BioPharma announces new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer (527.00a, 0.00)

• 07:03 AM ET Aug 12, 2026
  

  Can-Fite BioPharma provides an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson (524.00a, +23.00)

• 07:03 AM ET Aug 03, 2026
  

  Can-Fite BioPharma submits Phase 2 clinical study protocol to hospital in Italy for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome (509.00a, -7.00)

• 07:02 AM ET Jul 14, 2026
  

  Can-Fite BioPharma secures Australian patent allowance supporting namodenoson development and marketing in liver and pancreatic cancer (498.00a, 0.00)

• 07:03 AM ET Jul 06, 2026
  

  Can-Fite BioPharma completes enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. (565.00a, -19.00)

• 07:02 AM ET Jul 01, 2026
  

  Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease (414.00a, +5.00)

• 07:08 AM ET Jun 26, 2026
  

  Can-Fite secures Japanese patent allowance for Namodenoson's anti-obesity technology (449.00a, -11.00)

• 07:08 AM ET Jun 02, 2026
  

  Can-Fite BioPharma reports positive clinical observation in Phase 2a pancreatic cancer study and highlights namodenoson's RAS signaling inhibition mechanism (463.00a, +3.00)